recombinant adeno-associated virus 8 (aav8  (DIRUI Industrial Co Ltd)

Journal: Antioxidants

Article Title: Genetic and Pharmacological Inhibition of GCN2 Ameliorates Hyperglycemia and Insulin Resistance in Type 2 Diabetic Mice

doi: 10.3390/antiox11081584

Figure Lengend Snippet: GCN2 knockdown ameliorates metabolic disorders in db/db mice. Db/db mice were treated with AAV8-GFP or AAV8-sh Gcn2 via intravenous tail injection. After 4 weeks, the mice were sacrificed, and fasting blood glucose ( A ), serum insulin ( B ), AST ( C ), ALT ( D ), and TG ( E ) levels were measured. OGTT ( F ) and ITT ( G ) were performed on GFP- and sh Gcn2 -treated db/db mice and the corresponding AUC values in each group were calculated. ( H ) Representative liver sections were stained with H&E, oil red O, and DHE. Scale bar = 100 μm. Liver TG) ( I ), 3′-NT ( J ), and 4-HNE ( K ) levels were measured. ( L ) The mRNA levels of lipid metabolic genes were measured by qPCR. ( M ) Liver lysates were analyzed by Western blot. N = 5 ( A – L ) or 3 ( M ); values represent the mean ± SD; * indicates p < 0.05; ** indicates p < 0.01.

Article Snippet: Recombinant adeno-associated virus serotype 8 (AAV8)-GFP and AAV8-sh Gcn2 (targeting sequence: 5′-GGTATACAATGCTTTGGAA-3′) were obtained from Vigene Biosciences.

Techniques: Injection, Staining, Western Blot